What Happened?
Greenwich, PA-based Renovacor Appointed Kumar Dhanasekharan as Senior Vice President of Technical Operations
About the Company
Renovacor is a preclinical gene therapy company developing a pipeline of innovative and proprietary AAV based gene therapies for BAG3 gene mutation-associated diseases in areas of high unmet medical need. Renovacor`s therapeutic focus is initially on cardiovascular disease, with a lead program in BAG3 mutation-associated dilated cardiomyopathy.
About the Person
Kumar Dhanasekharan is Senior Vice President of Technical Operations at Renovacor. Previously, Kumar held various senior IT leadership roles in the industry.
Info Source
News
Short Profile